Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have launched a clinical trial, called ANDROMEDA, to ...

A multitargeted T-cell therapy produced encouraging activity in a preliminary study of patients with pancreatic cancer, ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Bi opsy of the P rostate A voidance S ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

The patients received Lutetium (177Lu) rhPSMA-10.1 Injections at both St Bartholomew's Hospital, London, and The James Cook University Hospital, Middlesbrough -- Lutetium (177Lu) rhPSMA-10.1 Injection ...

Mayo Clinic's Department of Radiation Oncology has launched the PSA Control Tower, an innovative tool designed to enhance the ...

Cancer diagnoses are both more common and more survivable than ever. The question is whether you can afford life-saving ...

Profound is a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue.

In a previous study, the researchers showed that PSA scores can impact both doctor and patient behavior, leading to biopsy ...